"Roche CFO Urges Strengthening Late-Stage Drug Development"

Roche's CFO, Alan Hippe, has emphasized the need for stronger drug development projects in advanced stages to boost the company's declining stock market value. Roche experienced setbacks in its late-stage pipeline last year, leading to a drop in share price. CEO Thomas Schinecker aims to restore Roche's drug development record and is considering potential acquisitions to achieve this goal. Roche is reportedly in talks to acquire an experimental drug from Roivant in a deal valued at over $7 billion. The company recently agreed to pay $310 million upfront to Alnylam for co-development rights to a drug candidate for high blood pressure.